Compare Cisco Systems Inc (CSCO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cisco Systems Inc vs BIO-TECHNE Corp — how do they compare? Cisco Systems Inc trades at $116.2 (market cap $452.96B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Cisco Systems Inc is far larger — about 39.9× BIO-TECHNE Corp's market cap, and Cisco Systems Inc pays the higher dividend (1.46%). Which is the better fit depends on your goals — on Pluang, investors hold Cisco Systems Inc for 86 Days and BIO-TECHNE Corp for 63 Days on average.
| CSCO | TECH | |
|---|---|---|
Market Cap | $452.96B | $11.36B |
Volume | 12,951,578 | 5,390,331 |
Sector | Technology | Health |
52-Week High | $130.00 | $72.61 |
52-Week Low | $67.46 | $43.31 |
Typical Hold Time | 86 Days | 63 Days |
Enterprise Value | $466.58B | $11.39B |
Dividend Yield | 1.46% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cisco Systems (CSCO) trades at $117.39, down 0.47% on the day, with a bullish technical signal from moving averages but overbought short-term RSI. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.22, and revenue growth is supported by AI-driven networking demand. Valuation ratios are elevated with a P/E of 34.5, while profitability remains robust with a net income margin of 20.95%.
The outlook is positive given AI infrastructure growth and consistent earnings beats, but high valuation and competitive pressures pose risks. Analyst consensus is bullish with a $129.77 price target, implying potential upside. Key risks include execution challenges in integrating AI innovations and macroeconomic sensitivity.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $1.22B, with a net income margin of 14.97%. Valuation ratios are elevated, with a P/E of 62.46 and P/S of 9.36. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The outlook is heavily influenced by the pending acquisition, offering a near-term price ceiling. Fundamentals show solid profitability but high valuation multiples. Risks include acquisition deal completion uncertainty and integration challenges. Analyst sentiment is mixed with no sell ratings, but the consensus price target of $65.78 suggests limited upside from current levels, making the stock a hold pending acquisition closure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cisco Systems Inc
Cisco Systems, Inc. provides information technology and networking services. The Company offers enterprise network security, software development, data collaboration, cloud computing, and other related services. Cisco Systems serves customers in the United States.
Read more on CSCO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
